4. References

  1. IBM Micromedex® DRUGDEX® (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: https://www-micromedexsolutions-com.libproxy.uthscsa.edu/ (cited: August 25, 2023).
  2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2023. Available at: http://clinicalpharmacology-ip.com.ezproxy.lib.utexas.edu/. Accessed August 25, 2023.
  3. Quetiapine tablets (Seroquel®) package insert. AstraZeneca Pharmaceuticals, January 2022.
  4. Quetiapine extended-release tablets (Seroquel XR®) package insert. AstraZeneca Pharmaceuticals, January 2022.
  5. Cohrs S, Rodenbeck A, Guan Z, et. al. Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology. 2004;174:421-9.
  6. Klimm HD, Dreyfus JF, Delmotte M. Zopiclone versus nitrazepam: a double-blind comparative study of efficacy tolerance in elderly patients with chronic insomnia.  Sleep. 1987;10(1):73-8.
  7. Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2:297-307.
  8. Juri C, Chana P, Tapia J, et al. Quetiapine for insomnia in Parkinson’s disease: results from an open label trial. Clin Neuropharmacol. 2005;28(4):185-7.
  9. Fernando A, Auckland GC. Chronic insomnia secondary to chronic pain responding to quetiapine. Australas Psychiatry. 2005;13(1):86.
  10. Sokolsji KN, Brown BJ. Quetiapine for insomnia associated with refractory depression exacerbated by phenelzine. Ann Pharmacother. 2006;40:567-70.
  11. Wiegand MH, Landry F, Buckner T, et al. Quetiapine in primary insomnia: a pilot study. Psychopharmacology. 2008;196:337-8.
  12. Teran A, Majadas S, Galan J. Quetiapine in the treatment of sleep disturbances associated with addictive conditions: a retrospective study. Subst Use Misuse. 2008;43:2169-71.
  13. Pasquini M, Speca A, Biondi M. Quetiapine for tamoxifen-induced insomnia in women with breast cancer. Psychosomatics. 2009;50(2):159-61.
  14. Cates ME, Jackson CW, Feldman JM, et al.  Metabolic consequences of using low-dose quetiapine for insomnia in psychiatric patients. Community Ment Health J. 2009;45:251-4.
  15. Tassniyom K, Paholpak S, Tassniyom S, Kiewyoo J. Quetiapine for primary insomnia: a double-blind, randomized controlled trial. J Med Assoc Thai. 2010;93(6):729-34.
  16. Wine JN, Sanda C, Caballero J. Effects of quetiapine on sleep in nonpsychiatric and psychiatric conditions. Ann Pharmacother. 2009;43:707-13.
  17. Anderson SL, Vande Griend JP. Quetiapine for insomnia: A review of the literature. Am J Health-Syst Pharm. 2014;71(5):394-402.
  18. Gugger JJ, Cassagnol M. Low-dose quetiapine is not a benign sedative-hypnotic agent. Am J Addict. 2008;17(5):454-5.
  19. Zarowitz BJ. Quetiapine not quiet-a-pine- not a sleeper. Geriatr Nurs.  2011;32(1):46-8.
  20. Højlund M, Andersen K, Ernst MT, Correll CU, Hallas J. Use of low-dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator-controlled cohort study. World Psychiatry. 2022 Oct;21(3):444-451.
  21. Coe HV, Kong IS. Safety of low doses of quetiapine when used for insomnia. Ann Pharmacother. 2012;46(5):718-22.
  22. Drugs for chronic insomnia. Med Lett Drugs Ther. 2018 Dec 17;60(1562):201-5.
  23. Agency for Healthcare Research and Quality. Off-label use of atypical antipsychotics: an update. Executive Summary. Comparative Effectiveness Review No. 43. (AHRQ Pub. No. 11-EHC087-1). Available at:  https://www.ncbi.nlm.nih.gov/books/NBK66081/pdf/Bookshelf_NBK66081.pdf. Accessed August 28, 2023.
  24. Sajatovic M, Madhusoodanan S, Coconcea N. Managing bipolar disorder in the elderly: defining the role of the newer agents. Drugs Aging. 2005;22:39-54.
  25. Yang CH, Tsai SJ, Wsang JP. The efficacy and safety of quetiapine for treatment of geriatric psychosis.  J Psychopharmacol. 2005;19:661-6.
  26. Tariot PN, Ismail MS. Use of quetiapine in elderly patients. J Clin Psychiatry. 2002;63(Suppl13):21-6.
  27. Texas Health and Human Services. Psychotropic medication utilization parameters for children and youth in Texas public behavioral health (6th version), June 2019. Available at: https://hhs.texas.gov/sites/default/files/documents/doing-business-with-hhs/provider-portal/facilities-regulation/psychiatric/psychotropic-medication-utilization-parameters.pdf. Accessed August 28, 2023.  
  28. Stathis S, Martin G, McKenna JG. A preliminary case series on the use of quetiapine for posttraumatic stress disorder in juveniles within a youth detention center.  J Clin Psychopharmacol. 2005;25:539-44.
  29. Findling RL, Reed MD, O’Riordan MA, et al. Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder.  J Am Acad Child Adolesc Psychiatry. 2006;45:792-800.
  30. Marchand WR, Wirth L, Simon C. Quetiapine adjunctive and monotherapy for pediatric bipolar disorder: a retrospective chart review. J Child Adolesc Psychopharmacol. 2004;14:405-11.
  31. Findling RL, McNamara NK, Gracious BL, et al. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol. 2004;14:287-94.
  32. Mukaddes NM, Abali O. Quetiapine treatment of children and adolescents with Tourette's disorder. J Child Adolesc Psychopharmacol. 2003;13:295-9.
  33. Tufan AE. Adjunctive quetiapine may help depression comorbid with pervasive developmental disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1570-1.
  34. Arango C, Robles O, Parellada M, et al. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry. 2009;18:418-28.
  35. Findling RL, Reed MD, O’Riordan MA, et al. A 26-week open-label study of quetiapine in children with conduct disorder. J Child Adolesc Psychopharmacol. 2007;17(1):1-9.
  36. Duffy A, Milin R, Grog P. Maintenance treatment of adolescent bipolar disorder: open study of the effectiveness and tolerability of quetiapine. BMC Psychiatry. 2009;9(4).
  37. Kronenberger WG, Giauque AL, Lafata D, et al. Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid attention-deficit/hyperactivity disorder, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study. J Child Adolesc Psychopharmacol. 2007;17(3):334-7.
  38. Golubchik P, Sever J, Weizman A. Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial.  Clin Neuropharmacol. 2011;34(6):216-9.
  39. Moreno C, Merchan-Naranjo J, Alvarez M, et al. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. Bipolar Disord. 2010;12:172-84.
  40. Penzner JB, Dudas M, Saito E, et al. Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol. 2009;19:563-73.